Get started
AGILENT TECHNOLOGIES INC COM STK USD0.01AGILENT TECHNOLOGIES INC COM STK USD0.01AGILENT TECHNOLOGIES INC COM STK USD0.01

AGILENT TECHNOLOGIES INC COM STK USD0.01

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

0HAV trade ideas

Agilent Technologies | Chart & Forecast SummaryKey Indicators on Trade Set Up in General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Active Sessions on Relevant Range & Elemented Probabilities; * Asian(Ranging) - London(Upwards) - NYC(Downwards) * Weekend Crypto Session # Trend | Time Frame Conductive | Weekly Time Frame - General Trend - Measurement on Session * Support & Resistance * Trade Area | Focus & Motion Ahead # Position & Risk Reward | Daily Time Frame - Measurement on Session * Retracement | 0.5 & 0.618 * Extension | 0.786 & 1 Conclusion | Trade Plan Execution & Risk Management on Demand; Overall Consensus | Buy
CAPITALCOM:ALong
by P-Ment4U
$A - AGILENTHigher Time Frame (HTF) analysis on the weekly TF. Clear Bearish bias with last leg up not running the previous key swing high, price sharply reversed and has left behind a liquidity void above (could yield higher prices to collect orders in that area), but overall, we appear to have a repeat of bullish turned bearish market sentiment. Since the ATH, we can see price has retraced -37% before putting in a new LH then sharply returning to break the support below, and has since repeated yielding similar percentage moves. If bias and structure maintain the current bearish sentiment, i would anticipate the 90$ range to be the next area of orders to be ran. No personal holdings or bias for this stock, i do have close friends that work for the company and hold shares, so ive tried to keep my analysis as unbiased and completely impartial.
NYSE:AShort
by TuataraW20
Agilent Reports Second-Quarter Fiscal Year 2024 Financial ResultAgilent Technologies Inc. (NYSE: NYSE:A ) reported a revenue of $1.57 billion for the second quarter of fiscal year 2024, down 8.4% reported and 7.4% core compared to the second quarter of 2023. GAAP net income was $308 million, with earnings per share (EPS) of $1.05, up 3% from the second quarter of 2023. Non-GAAP(2) net income was $356 million, with EPS of $1.22, down 4% from the second quarter of 2023. The full-year revenue outlook was revised at $6.420 billion to $6.500 billion, representing a range of down 6.0% to 4.9% on a reported basis and down 5.4% to 4.3% core. Fiscal year 2024 non-GAAP(3) earnings guidance was revised at a range of $5.15 to $5.25 per share. The company plans to repurchase $0.75 billion of its common stock by the end of the fiscal year, and the board recently authorized a new $2.0 billion share repurchase program. The company's president and CEO, Padraig McDonnell, expressed confidence in the future and excited about the opportunities that lie ahead for Agilent. In the first quarter of 2024, Agilent (NYSE: NYSE:A ) implemented certain changes to its segment reporting structure, which have no impact on its consolidated financial statements. The Life Sciences and Applied Markets Group reported second-quarter revenue of $754 million, a decline of 14% reported and 13% core year-over-year. The Agilent CrossLab Group (NYSE: NYSE:A ) reported second-quarter revenue of $402 million, an increase of 4% reported and 5% core year-over-year. The Diagnostics and Genomics Group reported second-quarter revenue of $417 million, a decrease of 9% reported and 8% core year-over-year. The full-year revenue outlook is revised at $6.420 billion to $6.500 billion, representing a range of down 6.0% to 4.9% on a reported basis and down 5.4% to 4.3% core. The outlook for third-quarter revenue is expected in the range of $1.535 billion to $1.575 billion, a decline of 8.2% to 5.8% reported and 6.9% to 4.5% core. Technical Outlook Agilent ( NYSE:A ) stock is down 18.36% in pre-market trading on Thursday starting on a rough slate it technically means Agilent stock is in a oversold region forming a downside gap. Gapping occurs in trading when there is no trading activities that occur but a stock is under-performing or outperforming prior to a fundamental.
NYSE:AShort
by DEXWireNews
A - fall -11.59% to $1.22 per share on February 27The last earnings report on October 31 showed earnings per share of $1.38, beating the estimate of $1.35. P/B Ratio (6.618) is normal, around the industry mean (25.768). P/E Ratio (31.511) is within average values for comparable stocks, (78.874). Projected Growth (PEG Ratio) (2.536) is also within normal values, averaging (6.641). Dividend Yield (0.007) settles around the average of (0.019) among similar stocks. P/S Ratio (5.721) is also within normal values, averaging (41.728). With 1.88M shares outstanding, the current market capitalization sits at 38.69B.
NYSE:A
by tickeron
NYSE-A - a good time to buy! (indicator Thewaved)The last signal to buy on this strategy was given September 15. The price of the asset at the time of entry into the trade was 113.79. Our goals for this trade are as follows. Take-Profit is set at 227.6. and Stop-Loss Order at 96.7 At the moment, the price is moving well in the signal direction, and we we have already had a profit of 1.6%. By the way, this happens quite often after the previous trade is closed by stop, so we opened the position with a good discount. And if we look back, what are we observing then several Long signals in a row - closed by stop-loss order and this gives a great probability of the descending trend reversal. In addition, at the entrance to the purchase, we have already had a great advantage over a huge number of investors. And the most important thing that I want to mention is that the price of the last entrance to the position is higher than the previous exit, and this almost always suggests that there will be a slight price reduction to remove the stop loss orders of other players who has a position at the moment. And such an action can take place several times. And now let's move on to the most important part, statistics. What do we see from the results The total income on strategy we have 222.87%. The percentage of profitable trades is not so important to us, since the general profit is satisfactory. The profit factor equals 1.801 and this is an excellent result. And all the closed trades in our strategy are 23.
NYSE:ALong
by brandlabelden
1
AGILENT Stock Chart Fibonacci Analysis 071623 Trading Idea 1) Find a FIBO slingshot 2) Check FIBO 61.80% level 3) Entry Point > 119/61.80% Chart time frame : B A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress : A A) Keep rising over 61.80% resistance B) 61.80% resistance C) Hit the bottom D) Hit the top Stocks rise as they rise from support and fall from resistance. Our goal is to find a low support point and enter. It can be referred to as buying at the pullback point. The pullback point can be found with a Fibonacci extension of 61.80%. This is a step to find entry level. 1) Find a triangle (Fibonacci Speed Fan Line) that connects the high (resistance) and low (support) points of the stock in progress, where it is continuously expressed as a Slingshot, 2) and create a Fibonacci extension level for the first rising wave from the start point of slingshot pattern. When the current price goes over 61.80% level , that can be a good entry point, especially if the SMA 100 and 200 curves are gathered together at 61.80%, it is a very good entry point. As a great help, tradingview provide these Fibonacci speed fan lines and extension levels with ease. So if you use the Fibonacci fan line, the extension level, and the SMA 100/200 curve well, you can find an entry point for the stock market. At least you have to enter at this low point to avoid trading failure, and if you are skilled at entering this low point, with fibonacci6180 technique, your reading skill to chart will be greatly improved. If you want to do day trading, please set the time frame to 5 minutes or 15 minutes, and you will see many of the low point of rising stocks. If want to prefer long term range trading, you can set the time frame to 1 hr or 1 day.
NYSE:A
by fibonacci6180
ABC DEarnings Beat. ABC Bullish pattern. Today, after the beat, CD is equal to AB. You can use the magnet to move the AB leg and project it up from C. The Auto-Fib tool on here helps you find C. C will be at the 0 fib level if it is an ABC pattern. The target is D but D can be in several different levels. In the bearish version, leg AB would be Down. This pattern reverses when D is met. I am not sure price is at D, so I will watch price/candles, and volume. The overall market movement can also influence targets. Unfortunately CD does not always equal AB and can be a lesser or greater fib level than 100%. I use the .382, .618 and .786 for smaller fib levels. If this passes the 1 (100%), I use the 1.272 and the 1.618. So this can go higher, but I would be tightening my stop at this point. (Actually I sold it at market open and it may have been too soon)o: Any pattern can fail, an could d always be on the look out for other patterns. There is a possible W pattern forming in this chart as well. No recommendation. If you look inside the ABC portion, there is an M pattern that measures out to be a Bullish Gartley. Leg 2 of the M hit the .618 and leg 4 hit the .786 of the first leg in the M pattern. Peak 2 is lower than peak 1. I did not draw that on here as it was not my focus for this chart. My point being there are often 2 or more patterns going on at once making Technical Analysis a tough sport (o:
NYSE:A
by lauralea
1
$A FORECASTAgilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable it to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA. NGL APDN INSPIRED
NYSE:AShort
by Bekiumuzi_Dube